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ABSTRACT 
Aims To assess the standing of acupuncture as a clinical tool in the management of trigeminal 
neuralgia against the current first-line drug and the most effective surgery. 
Methods Data regarding efficacy, side-effects, and cost were compiled for each of the three 
modalities from the PubMed and Cochrane Library databases. Patient stress was estimated 
according to Holmes and Rahe’s Social Readjustment Rating Scale (SRRS). 
Results Acupuncture is not significantly more effective than its corresponding control (p=0.088), but 
has the greatest mean efficacy of the modalities considered (acupuncture 86.5% ±5.6% (95% 
confidence interval), surgery 79.3% ±7.7%, pharmacotherapy 71.7% ±2.5%). Acupuncture also had 
fewer mean reported side-effects (acupuncture 22.7% ±5.9%, surgery 25.3% ±12.6%, 
pharmacotherapy 88.8% ±25.0%) and lowest cost: after 5 years acupuncture cost £750, 
carbamazepine £1507.73 and microvascular decompression £4878.42. Acupuncture was the least 
stressful according to the SRRS (53 points), surgery the next most stressful (153 points) and 
pharmacotherapy was the most stressful intervention to patients (217 points). 
Conclusion Acupuncture appears more effective than pharmacotherapy or surgery. Statistical 
analysis of side-effects was not possible due to inconsistent reporting protocols, but the data 
indicate acupuncture is considerably safer than pharmacotherapy or surgery. Acupuncture is also the 
least expensive therapeutic modality to deliver long-term (67 weeks onwards), and our analysis 
indicates that it is less stressful to patients than pharmacotherapy or surgery. Further study into 
these areas and the practicality of its availability on the NHS is recommended. 
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INTRODUCTION 
Trigeminal neuralgia (TN) is characterised by excruciating, burning pain along one or more branches 
of the trigeminal nerve, which can be triggered by innocuous stimuli like talking, chewing, or shaving, 
and may last seconds to minutes. In most cases, TN is caused by compression of the nerve root by an 
aberrant artery as it leaves the pons. 
Affecting up to 26.8 individuals per 100,000, TN is primarily seen in the 6th decade of life or later. 1 
Treatments for TN are broadly classified into three divisions: 
1. Surgery. Surgical interventions are generally classified into three sub-types: 
i. Microvascular decompression (MVD): craniotomy and placement of a Teflon sponge 
to protect nerve root from arterial pulsation. 
ii. Percutaneous interventions: including glycerol rhizotomy, radiofrequency lesioning, 
and balloon compression. 
iii. Stereotactic radiosurgery: focused ionising radiation damaging the nerve root, 
preventing pain signal transmission. 
2. Pharmacotherapy. NICE Guideline CG173 states carbamazepine is the first-line drug for TN. 
Carbamazepine inhibits voltage-gated Na channels in neurones, 1 reducing the frequency of 
pain signals processed by the central nervous system. 
3. Complementary. Recent research suggests acupuncture may alleviate TN symptoms. 
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METHODS 
Literature Search 
Two acupuncture studies were sourced from the Cochrane Library, with the remainder found on 
PubMed. The reference lists within these papers provided supplementary titles. PubMed search 
terms were: “acupuncture AND trigeminal” (n=217 results), “trigeminal neuralgia AND microvascular 
decompression” (n=959), and “carbamazepine AND trigeminal neuralgia” (n=722). Filters “Species: 
Human”, “Full Text” and “Language: English” were applied, giving 272 results (acupuncture = 17, 
microvascular decompression = 206, pharmacotherapy = 49). The filtered titles were then assessed, 
and papers aligning with the scope of this study were selected. 
Multifactorial Comparison 
It is beyond the scope of this study to consider all surgical options available, therefore MVD was 
selected to be the focus of the surgical arm of the comparison. While it is understood that MVD is 
not representative of the whole gamut of surgical options (MVD is an open procedure, while many 
others - including balloon compression, glycerol rhizotomy, or stereotactic radiosurgery - are 
percutaneous or entirely non-invasive) , it is reported to have the best long-term results with the 
lowest recurrence rate, and relatively few complications.2 
Carbamazepine is the focus of the pharmacotherapeutic arm of the comparison as it is the current 
first-line NICE-recommended therapy. 
A structured comparison of the three management modalities for TN was performed based on four 
key elements: 
1. Efficacy – efficacy rates were often reported within studies. These are usually percentages of 
patients experiencing ‘significant improvement’ under a given treatment. Statistical testing 
for significant differences between modalities’ success rates was conducted using a one-way 
Kruskal-Wallis test for independent samples after data from the literature was compiled. 
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2. Side-effects and complications – while mentioned in some studies, additional studies 
focusing on side-effects were included. Obtaining directly comparable data on side-effects 
was challenging and did not support statistical analysis. 
3. Patient stress – considered in this study through the impact to a patient’s lifestyle caused by 
each modality using the Holmes & Rahe Social Readjustment Rating Scale (SRRS). 3 Stress to 
patients is not often considered in studies assessing treatment efficacy, and as such no 
stress-assessing protocols were followed at the point of primary data collection. Therefore, 
the SRRS is the only protocol available to assess stress levels caused by each modality in the 
context of this study. Statistically analysing summed stress scores like these is impossible; 
the outcome would be meaningless as the summed score represents a sample of n=1. 
Instead, Jaccard coefficients for score distribution for each pair of modalities were 
calculated. This offers a quantitative opportunity to evaluate similarity in stress profiles. 
4. Cost – cost for acupuncture treatment on the NHS was found on the British Medical 
Acupuncture Society website and through personal communication (Cummins, M. (2017), 
Personal communication.). NICE issued a costing report including carbamazepine which was 
used to assess pharmacotherapy cost. 4 There were no reports of MVD cost to the NHS and, 
when contacted, NICE, NHS England and NHS Improvement were unable to provide the 
information. Instead, reported surgical costs from two papers 5,6 were converted to GBP 
considering the appropriate average annual exchange rates for those years. 
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RESULTS 
Acupuncture 
Efficacy rates for all modalities are summarised in Table 1. 
Side-effects from acupuncture are rare: one study reported 2,108 negative side-effects from 9,277 
treatments 7 and another showed 2,178 negative side-effects from 31,822 treatments: 8 a combined 
10.4% risk. Most commonly reported were: transient symptom exacerbation, bleeding, and 
administrative problems (eg needles lost). On the whole, acupuncture side-effects are mild (not life-
threatening); however, from 302,636 acupuncture treatments, 9,10 3 cases of iatrogenic 
pneumothorax were reported: less than a 0.001% risk.  
Acupuncture in NHS primary care costs £25 per treatment. The cost-assessment model used was: 12 
initial sessions (6 weekly treatments, then 6 monthly treatments) with quarterly ‘maintenance’ 
treatments. 
Surgery 
MVD is often studied in the context of differing efficacy rates between young and elderly patients. 
11–14 The initial limitation is the lack of consensus defining “elderly”. Papers with a defining age of 
>60 years were included in this study, including a larger proportion of data.  
Side-effects and complications of MVD are serious, including: meningitis, cerebrospinal fluid (CSF) 
leak, and death. Four studies discussed side-effect and complication frequency: 11–14a Mann-Whitney 
U test found no significant difference in rates of complications per patient (N=8, U=13, p=0.200). 
MVD cost was approximated at £4878.42 per surgery. 
Pharmacotherapy 
It is estimated that 75% of patients undergoing carbamazepine therapy experience symptomatic 
relief. 1 Despite this efficacy, many patients will experience side-effects including cognitive 
suppression, dizziness, cardiovascular disturbance, and the inflammatory skin reaction Stevens-
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Johnson Syndrome (SJS). 15,16 These may seriously affect patient stress, not just in initial diagnosis 
but throughout subsequent treatment and its side-effects which may cause lifestyle changes. 
NICE’s costing statement for carbamazepine therapy 4 shows 28x 200mg carbamazepine tablets 
costing £5.78. In the statement, prices are rounded too early, causing a slight inaccuracy. This 
equation demonstrates the calculation of daily (A) and annual (B) costs of a normal daily 
carbamazepine dose – 800mg: 4 
𝐴 = (
£5.78
28
) × 4 = £0.8257 
𝐵 = 𝐴 × 365 = £301.3805  
Carbamazepine costs 82.6p per day: £301.38 annually.  
Table 1 - comparing successful treatments across all modalities. *Al-Quiliti et al quote a 75% success rate for 
carbamazepine without providing raw data. As such, arbitrary figures have been included so this figure can be used in the 
comparison. 
STUDY PATIENTS IN TREATMENT 
ARM(S) (N) 
“CURED” OR “SIG. 
IMPROVEMENT” (N) 
SUCCESS RATE (%) 
 ACUPUNCTURE  
17 30 23 76.7 
18 86 72 83.7 
19 57 56 98.2 
20 65 57 87.7 
21 90 77 85.6 
22 62 54 87.1 
Total 392 341 86.5 
SURGERY 
13 124 73 58.9 
12 99 88 88.9 
11 59 50 84.7 
23 13,805 11,596 84.0 
24 31 25 80.6 
25 6,847 5,717 83.5 
26 53 47 88.7 
27 20 13 65.0 
Total 21,038 17,609 79.3 
PHARMACOTHERAPY 
1 100* 75* 75.0 
28 123 88 71.5 
29 81 55 67.9 
Total 304 218 71.5 
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Statistical Analysis  
A one-way Kruskal-Wallis test for independent samples found the three modalities’ efficacy rates 
were not statistically significant (DF=2, H=4.850, p=0.088), likely due to small sample sizes (n=6, 8 
and 3 respectively for acupuncture, surgery, and pharmacotherapy). Statistical side-effect analysis 
proved impossible due to different measurement and reporting protocols between studies, but the 
data do suggest pharmacological interventions cause many more side-effects than acupuncture or 
surgery. Overall, acupuncture’s stress factor profile is the most distinctive – see Table 4 for scores. A 
score of 0 indicates no shared factors and 1 a complete overlap. Surgery and pharmacotherapy score 
0.625, indicating most shared stress factors and therefore a similar stress profile. 
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DISCUSSION 
Efficacy 
“Cured” in the context of TN studies represents no relapse of symptoms before the follow-up: from 
the papers, this ranges from two treatment cycles to six months.17–22In the literature, acupuncture’s 
“cured” rate is higher in the intervention arm than the control, excluding Yang et al 17 for whom no 
data concerning “cured” rates was available. This represents an average of 86.5% cases “cured” or 
“significantly improved” by acupuncture. Alleviation of pain may also be due to reduction of 
secondary myofascial pain which is known to develop in response to chronic pain stimuli:2  while not 
a management modality for TN directly, this is still a positive outcome which may indirectly manage 
symptoms. 
Eight MVD studies 11–13,23–27 had an average of 79.3% “cured” or “significantly improved”. Two 
studies collecting primary and secondary data on carbamazepine therapy 28,29 found a 70% efficacy 
rate, with a third reporting a 75% efficacy. Table 1 compares these data: acupuncture is the most 
effective modality (86.5%) and carbamazepine the least (71.5%). 
One study with 62 participants reported a mean reduction of 0.8 in the Visual Analogue Scale (VAS) 
from the baseline to the end of acupuncture treatment.30 This fell a further 0.9 points at a 6-week 
review. Both were statistically significant changes (p = <0.05). 
Another study 31 only had 15 participants but showed a similar pattern, with a reduction of 0.8 in the 
VAS from baseline to the end of treatment and again from the end of treatment to the 6-month 
review. 
Despite many studies reporting significant efficacy rates (and the percentage efficacy rates are 
suggestively higher for acupuncture than surgery or pharmacotherapy), our statistical analysis was 
inconclusive (p=0.088, Kruskal-Wallis). This is due to a small sample size and represents an area for 
future study. 
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Side-Effects 
Patient anonymisation limits side-effect analysis – it is impossible to calculate how many patients 
experienced >1 side-effect. While not a true risk representation, a percentage can be drawn from 
“side-effects reported (n)” and “patients (n)”. This limitation is common to all three modalities.  
Table 2 compares the data: pharmacotherapy causes significantly more side-effects than 
acupuncture or surgery (p = <0.01). Research suggests women have lower carbamazepine tolerance 
by a factor of approximately 1.5, 15 which may have some indication for varying serum drug level 
thresholds for symptoms between the sexes. 
Pharmacotherapy’s 88.8% side-effect is the highest of the modalities – acupuncture is lowest at 
22.7%. Variable reporting, small sample sizes of applicable papers and patient anonymisation 
prevent robust statistical analysis, but awareness of the difference in overall prevalence of side-
effects from pharmacotherapy and acupuncture/surgery is important for physicians and patients 
alike. 
Table 2 mean side-effect frequencies from the modalities: acupuncture 7,17,32, surgery 11,12,36,37,14,23–26,33–35 and 
pharmacotherapy 16,29,33,38,39 
Side-effect severity is also significant: rarely, acupuncture may exert serious side-effects (although 
these carry a minuscule risk). Pharmacotherapy brings substantial side-effects in cognitive 
suppression and the risk of SJS in those genetically predisposed; however, these should be 
considered against the severity of side-effects from surgery: death, meningitis, CSF leak or cranial 
nerve palsy. Surgical interventions may also significantly impact masticatory function or alter 
sensation.2 Each modality’s side-effects have differing effects on patient stress: 
MODALITY PAPERS (N) PATIENTS (N) SIDE-EFFECTS 
REPORTED (N) 
MEAN (CI) 
ACUPUNCTURE 3 9,308 2,113 22.7% (±5.9%) 
SURGERY 12 27,638 6,989 25.3% (±12.6%) 
PHARMACOTHERAPY 5 385 34 88.8% (±25.0%) 
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Patient Stress 
Evaluating patient stress is subjective, difficult and often overlooked, and there is no clinical 
definition or measurement scale for iatrogenic stress. On the other hand, some rating systems make 
it possible to account for the stress caused by some aspects of medical interventions: indeed, 
according to the SRRS, one MVD surgery can provide over half the points to predispose someone to 
moderate illness within 12 months 3 – see Table 3. 
 
Table 3 compares each modality’s SRRS score. Each receives a score of 53 – personal injury / illness – 
to account for the initial diagnosis of TN. MVD requires recovery leave from work and refraining 
from driving, and repeated prescriptions in England may be a drain on financial resources in lower-
income households, hence both represent a “change in financial state”. For the same reason, MVD 
scores for “change in work hours” and “change in social activities”. Carbamazepine’s cognitive 
suppression means it applies to all selected life events, earning it the highest score of 217. Within a 
12-month period, <150 points represents a 30% risk of illness, 150-300 a 50% risk and >300 an 80% 
risk. 3 
Table 3 - scores incurred by each modality according to Holmes & Rahe's Social Readjustment Rating Scale. 
Pharmacotherapy is the most stressful intervention according to the SRRS (217 points). Surgery is 
the next most stressful at 153, and acupuncture the least stressful with just 53 points from the initial 
diagnosis. Statistical analysis of these data is impossible, but Jaccard similarity indices demonstrate 
overlap of stress factors (Table 4): 
LIFE EVENT SURGERY PHARMACOTHERAPY ACUPUNCTURE 
PERSONAL INJURY / ILLNESS 53 53 53 
CHANGE IN FINANCIAL STATE 38 38 - 
CHANGE IN RESPONSIBILITIES AT WORK - 29 - 
REVISION OF PERSONAL HABITS 24 24 - 
CHANGE IN WORK HOURS / CONDITIONS 20 20 - 
CHANGE IN RECREATION - 19 - 
CHANGE IN SOCIAL ACTIVITIES 18 18 - 
CHANGE IN SLEEPING HABITS - 16 - 
TOTAL 153 217 53 
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 ACUPUNCTURE SURGERY PHARMACOTHERAPY 
ACUPUNCTURE 1 0.2 0.125 
SURGERY - 1 0.625 
PHARMACOTHERAPY - - 1 
Table 4 - Jaccard similarity coefficients for stress factor profiles of each modality. Jaccard coefficients compare 
presence/absence score distributions (eg stress factors) in multiple treatment types. 0 = no similarity, 1 = identical. 
These scores suggest acupuncture’s stress profile is most distinctive, scoring low compared to 
surgery/pharmacotherapy. Surgery and pharmacotherapy have a more similar stress profile, scoring 
0.625. 
Cost 
Figure 1 demonstrates the cost relationship of the three management modalities over a 30-year 
period. 
Acupuncture costs the NHS £25 per treatment – priced according to the standardised treatment 
plan, the cost rises sharply at first but after 65 weeks of treatment, acupuncture becomes the least 
expensive option. After 5 years of treatment, acupuncture represents half the cost of 
carbamazepine. In the 17th year of treatment, carbamazepine becomes more expensive than one 
MVD. Acupuncture remains the least expensive option until the 47th year of treatment, assuming 
that: 
1) The patient was young enough when diagnosed to live another 47 years (the global life 
expectancy is 71.4 years according to the WHO website, meaning the patient would have to 
be in their mid-twenties at diagnosis), and 
2) The next cheapest therapeutic intervention at the 47th year (MVD) had not failed by that 
point (MVD can fail after 20-26 years), 40 and 
3) Symptoms had not been alleviated before the 47th year of treatment: usually, acupuncture 
treatments are stopped after 4 quarterly treatments have elapsed with no relapse of 
symptoms. 
The costs demonstrated in Figure 1 assume no relapses, well-tolerated drugs or surgeries, and 
minimal impact of side-effects to present a simple image. 
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The long-term treatment required in cases of trigeminal neuralgia is met by a long-term cost 
analysis. Acupuncture very quickly becomes, and remains, the least expensive therapeutic arm of 
the three, and surgery the most expensive. 
Strengths and Limitations 
To the authors’ knowledge, this study is the first of its kind to compare these three TN management 
modalities. Further, it is believed to be the first three-way cost analysis, which may support the 
argument for clinical application of acupuncture. Although detailed statistical analysis of each 
modality’s outcomes was not possible, some preliminary quantitative evidence has been produced 
which may be developed as further efficacy, side-effects and stress research is conducted. The 
greatest statistical challenge was the sample sizes, limited by the wide scope of the study. 
This study’s main limitation is that patients facing surgery for TN are likely to have refractory TN; the 
effects of acupuncture on refractory and non-refractory TN have not been elucidated. Further, 
distinctions between surgical techniques are commonly noted throughout literature, as well as 
between medications; however, manual versus electroacupuncture has not been considered in a 
number of these studies. Another limitation is the subjectivity of patient stress and how it may be 
applied, especially quantitively. This will remain a challenge until stress measures are more routinely 
included in study findings, when statistical analysis may become possible. 
Conclusion 
This study shows that acupuncture treatment for TN is effective, safe, and cheaper to deliver than 
surgical or pharmacotherapeutic interventions. The results warrant further detailed research into 
the efficacy, patient stress and side-effects of acupuncture versus surgery and pharmacotherapy. 
Further research is also recommended to assess the practicality of offering acupuncture as a 
management modality for trigeminal neuralgia through the NHS. 
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Finally, treatments offered by the NHS must be cost-effective. While carbamazepine is less expensive 
than MVD, acupuncture is by far the least expensive option. Further research should be conducted 
with a view to considering acupuncture as a first-line therapy for TN. 
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